Intellia Therapeutics, INC Form 4 insider transactions

Director Frank Verwiel reports acquisition of stock options and restricted stock units in Intellia Therapeutics.

Director Georgia Keresty reports acquisition of Intellia Therapeutics stock and stock options, and disposal of stock.

Director Jesse Goodman reported the acquisition of 7,737 shares of common stock and 11,515 stock options, as well as the disposal of 19,453 shares of common stock.

Director Fred E. Cohen reports acquisition of 7,737 shares of common stock and an option to purchase 11,515 shares of Intellia Therapeutics.

Director Muna Bhanji reports acquisition of restricted stock units and stock options, along with disposal of common stock.

Director William J. Chase reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Laura Sepp-Lorenzino, EVP and Chief Scientific Officer of Intellia Therapeutics, reports the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

James Basta, EVP and General Counsel of Intellia Therapeutics, reports acquisition of restricted stock units and stock options, as well as a sale of shares to cover tax obligations.

Derek Hicks, EVP and Chief Business Officer of Intellia Therapeutics, reports the acquisition of stock options and restricted stock units.

EVP and Chief Technical Officer of Intellia Therapeutics, Eliana Clark, reports acquisition of restricted stock units and subsequent sale of shares to cover tax obligations.

Intellia Therapeutics' CEO, John M. Leonard, reports acquisition of restricted stock units and stock options, along with adjustments to shares held by a trust.

David Lebwohl, EVP and Chief Medical Officer of Intellia Therapeutics, reports acquisition of restricted stock units and stock options.

Glenn Goddard, EVP and CFO of Intellia Therapeutics, reports acquisition of restricted stock units and stock options, and disposal of common stock.